ibodutant ibodutant ibodutant was a candidate drug for irritable bowel syndrome diarrhea, developed by the menarini group. as of march 2015, it underwent a multicentre double blind efficacy clinical study. ibodutant selectively blocks the tachykinin receptor nk2, with blockade practically complete in nanomolar concentrations. a phase 2 trial in europe (the iris-2 trial) completed in may 2012 with positive results. a 52-week phase 3 study was terminated as of 2015 because of low response and negative results of study nak-06. ibodutantclinical dataother names6-methyl-n-methylamino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]cyclopentyl]-1-benzothiophene-2-carboxamideroutes ofadministrationoralatc codenoneidentifiers iupac name nα-amino}cyclopentyl)carbonyl]-n--d-phenylalaninamide cas number522664-63-7 ypubchem cid11527495iuphar/bps2117chemspider9702281 nunii1h7rsq28bjcomptox dashboard (epa)dtxsid20966639 chemical and physical dataformulac37h48n4o4smolar mass644.88 g·mol−13d model (jsmol)interactive image smiles cc1=cc2=c(c=c1)c=c(s2)c(=o)nc3(cccc3)c(=o)nc(cc4=cc=cc=c4)c(=o)ncc5ccn(cc5)cc6ccocc6 inchi inchi=1s/c37h48n4o4s/c1-26-9-10-30-23-33(46-32(30)21-26)35(43)40-37(15-5-6-16-37)36(44)39-31(22-27-7-3-2-4-8-27)34(42)38-24-28-11-17-41(18-12-28)25-29-13-19-45-20-14-29/h2-4,7-10,21,23,28-29,31h,5-6,11-20,22,24-25h2,1h3,(h,38,42)(h,39,44)(h,40,43)/t31-/m1/s1 nkey:yqysvmkcmiuchy-wjokgbtcsa-n n ny (what is this?) (verify)